Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia].

Literature DB >> 26518303

[S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia].

K Höfner¹, T Bach², R Berges³, K Dreikorn⁴, C Gratzke⁵, S Madersbacher⁶, M-S Michel⁷, R Muschter⁸, M Oelke⁹, O Reich¹⁰, C Tschuschke¹¹, T Bschleipfer¹².

Abstract

This report summarizes the relevant aspects of the S2e guideline of the German Urologists for the conservative and pharmacological treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Recommendations are given regarding watchful waiting, behavioral therapy, phytotherapy and pharmacological mono- and combination therapy. The influence of the different therapeutic options on bladder outlet obstruction (BOO) is described in detail.

Entities: Disease

Keywords: Behavioral therapy; Drug therapy, combination; Monotherapy, drug; Phytotherapy; Watchful waiting

Mesh：

Substances：

Year: 2016 PMID： 26518303 DOI： 10.1007/s00120-015-3984-z

Source DB: PubMed Journal: Urologe A ISSN： 0340-2592 Impact factor: 0.639

115 in total

Review 1. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors: Mauro Gacci; Giovanni Corona; Matteo Salvi; Linda Vignozzi; Kevin T McVary; Steven A Kaplan; Claus G Roehrborn; Sergio Serni; Vincenzo Mirone; Marco Carini; Mario Maggi
Journal: Eur Urol Date: 2012-02-25 Impact factor: 20.096

Review 2. Complementary and alternative medicine in urology.

Authors: Kurt Dreikorn
Journal: BJU Int Date: 2005-12 Impact factor: 5.588

3. Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group.

Authors: P Abrams; W Schäfer; T L Tammela; D M Barrett; H Hedlund; H J Rollema; A Matos-Ferreira; J Nordling; R Bruskewitz; J T Andersen; T Hald; P Miller; R Kirby; S Mustonen; A Cannon; C A Jacobsen; G J Gormley; M P Malice; M A Bach
Journal: J Urol Date: 1999-05 Impact factor: 7.450

Review 4. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.

Authors: Michael J Naslund; Martin Miner
Journal: Clin Ther Date: 2007-01 Impact factor: 3.393

Review 5. Urodynamic effects of various treatment modalities for benign prostatic hyperplasia.

Authors: J L Bosch
Journal: J Urol Date: 1997-12 Impact factor: 7.450

6. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.

Authors: G S Gerber; J H Kim; B A Contreras; G D Steinberg; D B Rukstalis
Journal: Urology Date: 1996-06 Impact factor: 2.649

7. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.

Authors: I R Katz; L P Sands; W Bilker; S DiFilippo; A Boyce; K D'Angelo
Journal: J Am Geriatr Soc Date: 1998-01 Impact factor: 5.562

8. Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement.

Authors: W P Witjes; M J de Wildt; P F Rosier; C T Caris; F M Debruyne; J J de la Rosette
Journal: J Urol Date: 1996-09 Impact factor: 7.450

9. Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon(R)) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors: S H Al-Shukri; P Deschaseaux; I V Kuzmin; R R Amdiy
Journal: Prostate Cancer Prostatic Dis Date: 2000-11 Impact factor: 5.554